SC
TARA icon

Stempoint Capital’s Protara Therapeutics TARA Stock Holding History

Stempoint Capital’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-87,900
Closed -$13.2K – 69
2024
Q1 		$13.2K Buy
+87,900
New +$284K ﹤0.01% 61

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Stempoint Capital's TARA Position: Q4 2025 in Review

Stempoint Capital sold out of Protara Therapeutics (TARA) in Q4 2025, closing a stake of 363,666 shares — an estimated $1.58M sold.

Stempoint Capital first reported a position in TARA in Q1 2024 and held it in 7 quarters. The position peaked at $5.07M in Q1 2025. 105 funds tracked by Wall St. Rank hold TARA as of Q4 2025.

  • Stempoint Capital reported no remaining Protara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stempoint Capital sold 363,666 Protara Therapeutics shares in Q4 2025, an estimated $1.58M.
  • Stempoint Capital first reported a position in Protara Therapeutics in Q1 2024 and held it in 7 quarters.
  • Stempoint Capital's Protara Therapeutics position peaked at $5.07M in Q1 2025.
  • 105 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.